Rosen Law Firm Launches Investigation into Tandem Diabetes Care
The global investor rights firm, Rosen Law Firm, has announced the commencement of an investigation concerning potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM). This inquiry arises from allegations that the company may have disseminated materially misleading information about its business operations, which has raised concerns among its investors. The firm is urging individuals who acquired shares of Tandem Diabetes to assess their eligibility for compensation, emphasizing that they can do so without incurring any upfront costs due to a contingency fee arrangement.
On August 7, 2025, prior to the opening of the stock market, Tandem Diabetes issued a press release regarding a voluntary medical device correction for select t:slim X2 insulin pumps. This announcement detailed a potential speaker-related issue that could lead to an interruption in insulin delivery, which is critical for users relying on this device. Following this disclosure, Tandem Diabetes experienced a significant stock decline, with shares plummeting by nearly 20% on the same day, reflecting investor concerns about the implications of the device correction.
Investor Rights and Class Action Details
In light of these developments, Rosen Law Firm is actively preparing a class action lawsuit aimed at recovering losses suffered by investors in Tandem Diabetes. Interested parties are encouraged to participate by contacting the firm directly or visiting their website to submit relevant information. Legal representatives from Rosen Law Firm, including attorney Phillip Kim, are available to provide further insights into the class action process and assist in guiding investors through their options.
The firm has a proven track record in handling securities class actions, having secured notable settlements in the past, including the largest settlement against a Chinese company at that time. Since 2013, it has consistently ranked among the top firms in the United States for the number of securities class action settlements, recovering hundreds of millions of dollars for aggrieved investors. The firm’s dedication to investor rights has positioned it as a reputable choice for individuals seeking legal counsel in the complex arena of securities litigation.
For updates and additional information, interested individuals can follow Rosen Law Firm on various social media platforms, including LinkedIn, Twitter, and Facebook. As this situation develops, the firm remains committed to providing comprehensive support for investors affected by the recent events surrounding Tandem Diabetes Care and its products.
Related
